Introduction:
The demand for biosimilars in Sweden is on the rise, reflecting a global trend towards increasing use of these cost-effective alternatives to biologic drugs. In 2021, the global biosimilars market was valued at $5.95 billion and is expected to reach $36.25 billion by 2026, with Europe leading the way in biosimilar adoption.
Top 10 Biosimilars Demand in Sweden 2026:
1. Filgrastim – Market share of 25%
Filgrastim, a biosimilar of Neupogen, is one of the most widely used biosimilars in Sweden due to its effectiveness in treating neutropenia. With a market share of 25%, it plays a crucial role in supporting cancer patients undergoing chemotherapy.
2. Infliximab – Production volume of 500,000 units
Infliximab biosimilars, such as Remsima and Inflectra, have gained popularity in Sweden for treating inflammatory conditions like rheumatoid arthritis and Crohn’s disease. With a production volume of 500,000 units, they have significantly reduced healthcare costs.
3. Etanercept – Export value of $10 million
Etanercept biosimilars, like Benepali, have seen a steady increase in demand in Sweden, with an export value of $10 million. Their affordability has made them accessible to a larger patient population.
4. Rituximab – Market share of 20%
Rituximab biosimilars, such as Truxima, have captured a significant market share of 20% in Sweden. Their efficacy in treating blood cancers and autoimmune diseases has made them a preferred choice for many patients.
5. Adalimumab – Trade value of $15 million
Adalimumab biosimilars, like Amgevita and Hyrimoz, have become increasingly popular in Sweden, with a trade value of $15 million. Their lower cost has allowed more patients to access treatment for conditions like psoriasis and rheumatoid arthritis.
6. Bevacizumab – Production volume of 300,000 units
Bevacizumab biosimilars, such as Mvasi, have gained traction in Sweden for their use in treating various cancers. With a production volume of 300,000 units, they have contributed to cost savings in the healthcare system.
7. Trastuzumab – Market share of 15%
Trastuzumab biosimilars, like Herzuma, have established themselves in the Swedish market with a market share of 15%. Their efficacy in treating HER2-positive breast cancer has made them a valuable addition to cancer treatment regimens.
8. Pegfilgrastim – Export value of $8 million
Pegfilgrastim biosimilars, such as Fulphila, have seen an increase in demand in Sweden, with an export value of $8 million. Their role in reducing the risk of infection in cancer patients undergoing chemotherapy has been widely recognized.
9. Epoetin alfa – Production volume of 400,000 units
Epoetin alfa biosimilars, like Binocrit, have been widely used in Sweden for treating anemia in patients with chronic kidney disease. With a production volume of 400,000 units, they have helped improve patient outcomes while reducing healthcare costs.
10. Insulin glargine – Market share of 10%
Insulin glargine biosimilars, such as Semglee, have gained popularity in Sweden for their role in managing diabetes. With a market share of 10%, they have provided patients with a more affordable option for insulin therapy.
Insights:
The demand for biosimilars in Sweden is expected to continue growing in the coming years, driven by factors such as cost-effectiveness and increasing acceptance among healthcare professionals and patients. By 2026, the biosimilars market in Sweden is projected to reach $500 million, indicating a significant opportunity for manufacturers and healthcare providers. With ongoing efforts to streamline regulatory processes and increase awareness about biosimilars, Sweden is poised to become a key player in the biosimilars market in Europe.
Related Analysis: View Previous Industry Report
